Basiliximab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Basiliximab and local guidelines before prescribing.
Immunosuppressant
Mechanism
Anti-IL-2 receptor monoclonal antibody.
Uses
Induction immunosuppression in renal transplantation.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infections, hypersensitivity, GI upset.
Interactions
Other immunosuppressants.
Contraindications and cautions
Hypersensitivity
Monitoring
Infection
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Given on day 0 and day 4.
More from the textbook: uses, cautions and other points
- Other targeted drugs (specialist) - basiliximab (induction), belatacept, plasma exchange (anti-GBM disease), avacopan (complement C5a receptor blocker in ANCA vasculitis - liver monitoring), eculizumab (atypical HUS - meningococcal vaccination ), targeted-release budesonide (IgA nephropathy).
Renal: Anatomy, Physiology and Pharmacology - Basiliximab (IL-2 receptor antibody) or alemtuzumab (anti-CD52, commonly used in the UK).
Renal: Dialysis and Transplant - Basiliximab / alemtuzumab | Induction agents at transplant.
Renal: Dialysis and Transplant - Cytokines - signalling proteins that coordinate immunity; many are now drug targets: Cytokine Main effects Blocked by TNF-α Inflammation, fever, cachexia, granuloma maintenance Infliximab, adalimumab, etanercept IL-1 Fever, inflammation - autoinflammatory diseases, gout Anakinra, canakinumab IL-6 Acute phase response (CRP), fever …
Clinical Immunology: Immune system basics and immunological investigations - IL-2 | T-cell proliferation | Tacrolimus, ciclosporin (reduce production); basiliximab (receptor)
Clinical Immunology: Immune system basics and immunological investigations - Induction - basiliximab (IL-2 receptor antibody) or anti-thymocyte globulin or alemtuzumab, with high-dose steroids.
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology